Risks

U.S. ophthalmic procedure volumes remain tied to elective care and reimbursement stability, but Cooper’s diversified contact lens and fertility mix should cushion demand better than pure-play peers.

Contact lens category growth is mature and promotion-sensitive, yet Cooper’s MyDay and clariti franchises support steadier share retention than smaller branded competitors.

Foreign-exchange and cross-border cost pressures can still compress reported margins, although Cooper’s global revenue base is less concentrated than many U.S.-only medtech peers.

Working-capital intensity remains elevated, with a 224-day cash conversion cycle, but Cooper’s recurring consumables model is structurally more resilient than capital-equipment peers facing lumpier collections.

Leverage is moderate at 2.6x net debt-to-EBITDA and 5.8x interest coverage, leaving less balance-sheet flexibility than top-tier peers if growth or pricing weakens.

Opportunities

Premium daily silicone hydrogel adoption continues to shift share toward higher-value lenses, and Cooper’s MyDay positioning gives it better mix upside than commoditized lens peers.

The fertility market remains structurally supported by delayed family formation and broader treatment access, and Cooper’s CooperSurgical exposure offers more durable growth than cyclical medtech peers.

International expansion in contact lenses can still outgrow the U.S. market, and Cooper’s global distribution footprint is broader than many niche ophthalmology competitors.

Recurring consumables demand supports steadier revenue visibility than procedure-dependent peers, which should help Cooper sustain growth through softer macro periods.

Product mix toward premium lenses and surgical consumables can support margin expansion, with Cooper better positioned than lower-priced peers to capture value from innovation.

Overall Score

Cooper’s forward positioning is strong because premium contact lenses, fertility exposure, and recurring consumables provide better growth visibility than most peers, while leverage and working-capital intensity remain manageable but notable constraints.